Payment overview · 2025
General Payments
$444.22
15 reported records · 8 companies
Healthcare provider profile · identity verified
Israel Willis
Allopathic & Osteopathic Physicians|General Practice · BRONX, NY · NPI 1932448701
Verified facts
What the public records show
CMS Open Payments records show Israel Willis received $444.22 in general payments during 2025 across 15 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 51.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $230.03 | 51.8% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.61 | 10.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.01 | 10.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.24 | 6.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.81 | 5.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.56 | 5.5% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $23.68 | 5.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.28 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $444.22 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $277.04 | 8 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.24 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.04 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 312 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 281 | 78 |
| Eliquis | Apixaban | 269 | 49 |
| Gabapentin | Gabapentin | 174 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 144 | 34 |
| Metformin Hcl | Metformin Hcl | 136 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 135 | 41 |
| Losartan Potassium | Losartan Potassium | 134 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 131 | 55 |
| Furosemide | Furosemide | 124 | 41 |
| Memantine Hcl | Memantine Hcl | 115 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 43 |
| Donepezil Hcl | Donepezil Hcl | 106 | 25 |
| Levetiracetam | Levetiracetam | 99 | 26 |
| Mupirocin | Mupirocin | 99 | 40 |
| Repaglinide | Repaglinide | 93 | 21 |
| Finasteride | Finasteride | 86 | 33 |
| Januvia | Sitagliptin Phosphate | 82 | suppressed |
| Amoxicillin | Amoxicillin | 81 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 40 |
| Famotidine | Famotidine | 76 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 74 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 22 |
| Latanoprost | Latanoprost | 69 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | 20 |
| Mirtazapine | Mirtazapine | 64 | 20 |
| Montelukast Sodium | Montelukast Sodium | 64 | 25 |
| Baclofen | Baclofen | 63 | 16 |
| Clotrimazole | Clotrimazole | 62 | 27 |
| Silver Sulfadiazine | Silver Sulfadiazine | 62 | 22 |
| Alendronate Sodium | Alendronate Sodium | 61 | 24 |
| Fluconazole | Fluconazole | 61 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 16 |
| Lisinopril | Lisinopril | 61 | 17 |
| Nifedipine Er | Nifedipine | 60 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 12 |
| Carvedilol | Carvedilol | 55 | 14 |
| Omeprazole | Omeprazole | 55 | 22 |
| Levofloxacin | Levofloxacin | 51 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 51 | 17 |
| Nystatin | Nystatin | 49 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 36 |
| Meloxicam | Meloxicam | 48 | 16 |
| Entresto | Sacubitril/Valsartan | 47 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | 14 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 45 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 13 |
| Methenamine Hippurate | Methenamine Hippurate | 43 | 16 |
| Novolog Flexpen | Insulin Aspart | 43 | 11 |
| Tramadol Hcl | Tramadol Hcl | 42 | 16 |
| Metformin Hcl Er | Metformin Hcl | 41 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 19 |
| Fenofibrate | Fenofibrate | 40 | 12 |
| Enalapril Maleate | Enalapril Maleate | 39 | 14 |
| Labetalol Hcl | Labetalol Hcl | 39 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 37 | suppressed |
| Valsartan | Valsartan | 37 | 11 |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Allopurinol | Allopurinol | 34 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 34 | 13 |
| Enulose | Lactulose | 34 | suppressed |
| Rexulti | Brexpiprazole | 34 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 33 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | 13 |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 24 |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Levemir Flexpen | Insulin Detemir | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 15 |
| Lorazepam | Lorazepam | 27 | suppressed |
| Simvastatin | Simvastatin | 27 | 12 |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 12 |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Tivicay | Dolutegravir Sodium | 22 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Pentasa | Mesalamine | 19 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 19 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 13 |
| Lidocaine | Lidocaine | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Prednisone | Prednisone | 18 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Admelog Solostar | Insulin Lispro | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Alogliptin | Alogliptin Benzoate | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Paroxetine Cr | Paroxetine Hcl | 16 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 16 | suppressed |
| Silodosin | Silodosin | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 15 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $444.22 · 15 records | Otsuka America Pharmaceutical, Inc. | BREZTRI, Cologuard Collection Kit, FARXIGA, MAVYRET, MOUNJARO, REPATHA, REXULTI, SKYCLARYS, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error